Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3039294 in Healthy Volunteers and Systemic Amyloidosis
NCT02603172Phase 1Terminated
- Sponsor
- GSK
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK3039294 in systemic amyloidosis (5 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Number of Participants With Emergent Clinical Chemistry by PCI Criteria and 5 more. Started May 2016; status: terminated.
02
Drugs
GSK3039294
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT02603172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603172.